Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Josh Disbrow will engage in a fireside chat on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time. The event is virtual, and interested parties can sign up to view the presentation through a provided link.
Following the event, one-on-one investor meetings will be available upon request. Investors can arrange these meetings by contacting their Maxim representative or Aytu's investor relations group at aytu@lythampartners.com.
Aytu BioPharma is a pharmaceutical company that focuses on commercializing novel therapeutics. This summit participation provides an opportunity for investors to gain insights into the company's operations and future plans.
Positive
- None.
Negative
- None.
News Market Reaction – AYTU
In the trading session that priced this news, AYTU gained 1.32%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time.
2024 Maxim Healthcare Virtual Summit Details
Format: Fireside chat
Date: Wednesday, October 16, 2024
Time: 2:00 p.m. Eastern time
Location: Virtual
To sign up to view the presentation, click here.
1x1 investor meetings will be available after the event upon request by contacting your Maxim representative or the Company's investor relations group at aytu@lythampartners.com.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on accesswire.com